Solid Tumor
Conditions
Brief summary
This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available. The purpose of this study is to evaluate how safe ramucirumab is and whether it causes any side effects. The study will also measure how much ramucirumab gets into the blood stream and how long it takes the body to get rid of it.
Interventions
BIOLOGICALRamucirumab
Administered IV.
Sponsors
Eli Lilly and Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chinese participants with histopathologically or cytologically diagnosed advanced solid tumor * Did not respond to standard therapy or no standard therapy is available * Measurable or nonmeasurable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 at study entry * Able to provide written informed consent * A life expectancy of \>3 months * Adequate hematologic function, as defined by: Absolute neutrophil count (ANC) ≥1500 per cubic millimeter (mm\^3); hemoglobin concentration ≥9 grams per deciliter (g/dL); and platelet count ≥100,000/mm\^3 * Adequate hepatic function, as defined by: Total bilirubin level ≤1.5 x the upper limit of normal (ULN) (in participants with known Gilbert Syndrome, a total bilirubin ≤ 3.0 x ULN with direct bilirubin ≤ 1.5 x ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (or ≤5 x ULN if the participant has liver metastases * Adequate renal function, as defined by: Serum creatinine level ≤1.5 x ULN; or calculated serum creatinine clearance (Cockcroft-Gault) ≥50 milliliters per minute (mL/min) * Urinary protein is 0 or 1+ on dipstick but no edema nor serum albumin \< lower level of normal * Adequate coagulation function, as defined by: International normalized ratio (INR) ≤1.5, or prothrombin time (PT) ≤1.5 x ULN and activated partial thromboplastin time (aPTT) ≤1.5 x ULN (unless receiving anticoagulation therapy) * Agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study treatment
Exclusion criteria
* Had chemotherapy or therapeutic radiotherapy within 14 days (6 weeks for nitrosoureas or mitomycin C) before entering the study or the participant has ongoing side effects (≥ Grade 2) due to previously administered agents * Has obvious evidence of intratumor cavitation * Has undergone major surgery within 28 days before study entry or has had a central venous access device inserted within 7 days before study entry * Has a history of gastrointestinal perforation, postoperative bleeding complications, or wound complications from a surgical procedure * Has elective or planned surgery to be conducted during the trial * Has documented and/or symptomatic brain or leptomeningeal metastases * Has uncontrolled ongoing illness, for example: thrombotic or hemorrhagic disorders; hemoptysis; ongoing infection requiring systemic antibiotic treatment; congestive heart failure, angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months; stroke, transient ischemic attack (TIA), or other grade 3-4 arterial thromboembolic event occurring within 6 months; uncontrolled hypertension (≥150/≥90 millimeters of mercury \[mmHg\]); cardiac arrhythmia that requires treatment or asymptomatic sustained ventricular tachycardia; peripheral neuropathy ≥Grade 2; human immunodeficiency virus (HIV) or active, uncontrolled hepatitis, liver cirrhosis at a level of Child-Pugh Class B (or worse), liver cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. (Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis) * Has a serious or nonhealing wound, ulcer, or bone fracture within 28 days before study entry * Has experienced any Grade 3 or 4 gastrointestinal bleeding within 3 months before study entry * Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess \<6 months before randomization, or the participant has a history of poorly controlled or recurrent inflammatory bowel disease (including Crohn's disease or ulcerative colitis) * Has participated in a clinical study of a non-approved experimental agent or procedure within 4 weeks prior to study entry for small molecules, or 8 weeks before study entry for non-approved monoclonal antibodies * Has a known allergy to ramucirumab or its excipients, a monoclonal antibody (MAb), or any other therapeutic protein, such as fresh frozen plasma, human serum albumin (HSA), cytokines, or interleukins. If there is suspicion that the participant may have an allergy, the participant should be excluded * Is pregnant (confirmed by urine or serum pregnancy test) or lactating * Has known alcohol or drug dependency * Is receiving chronic therapy with nonsteroidal anti-inflammatory agents (NSAIDs) * Is not considered to be suitable for this study, in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) | Baseline through Study Completion (Up to 12 Weeks) | A summary of AEs and SAEs considered by the investigator to be drug-related is located in the Reported Adverse Events module. An AE is summarized if the onset date is on or after the first dose of study drug and within 30 days after the last dose, or it occurred before the first dose of study drug and worsened while on the therapy. |
| Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab | Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only) | — |
| Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 2-5: Predose | — |
| Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only) | Cycle 1 analysis performed: Area Under the Concentration-Time Curve Zero to Infinity (AUC\[0-∞\]); Cycle 2 analysis performed: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC\[τ,ss\]) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | Time Between Meeting Response Criteria and Progressive Disease or Death Due to Any Cause (Up to 10 Weeks) | Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. For each participant who is not known to have died or to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, duration of tumor response was to be censored at the date of the participant's last objective tumor assessment prior to that cut-off date. |
| Number of Participants With Best Objective Response (BOR) | Baseline to Progressive Disease or Participant Stopped Study (Up to 10 Weeks) | Participants achieved disease control if they had a BOR of CR, PR or SD. Progressive Disease (PD) and those participants which were Not Evaluable (NE) were also reported. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. |
| Duration of Stable Disease (SD) | Baseline to Progressive Disease or Death Due to Any Cause (Up to 10 Weeks) | Duration of SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. SD is measured at the start of the study drug until progressive disease or death due to any cause, whichever is first. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis. |
| Time to Disease Progression | Baseline to Progressive Disease (Up to 10 Weeks) | Time to progressive disease was measured from the start of study drug until progressive disease. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis. |
| Number of Participants With Anti-Ramucirumab Antibodies | Cycle 1: Pre-infusion, Cycle 2: Pre-infusion, Cycle 3: Pre-infusion | A sample will be considered positive for circulating anti-ramucirumab antibodies if it exhibits a post-baseline antibody level that exceeds the upper 95% confidence interval of the mean determined from the normal anti-ramucirumab level seen in healthy untreated individuals. A participant will be considered to have an anti-ramucirumab response if there are 2 consecutive positive samples or if the final sample tested is positive. |
Countries
China
Participant flow
Pre-assignment details
Participant study completion is defined as a participant either completing all 6 cycles of study drug or discontinuing study drug due to dose-limiting toxicities (DLT), then completing all required End-of-Therapy and End-of-Study assessments.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 - 6 mg/kg/2w Ramucirumab 6 mg/kg ramucirumab administered IV every 2 weeks for 6 weeks (one cycle) followed by dose escalation to Cohort 2. When a pre-defined percentage of participants completed Cycle 1 without experiencing a DLT, dose escalation was initiated with the start of Cohort 2. | 6 |
| Cohort 2 - 10 mg/kg/3w Ramucirumab 10 mg/kg ramucirumab administered IV every 3 weeks for 6 weeks (one cycle) followed by dose escalation to Cohort 3. When a pre-defined percentage of participants completed Cycle 1 without experiencing a DLT, dose escalation was initiated with the start of Cohort 3. | 10 |
| Cohort 3 - 8 mg/kg/2w Ramucirumab 8 mg/kg ramucirumab administered IV every 2 weeks for 6 weeks (one cycle). | 12 |
| Total | 28 |
Baseline characteristics
| Characteristic | Cohort 1 - 6 mg/kg/2w Ramucirumab | Total | Cohort 3 - 8 mg/kg/2w Ramucirumab | Cohort 2 - 10 mg/kg/3w Ramucirumab |
|---|---|---|---|---|
| Age, Continuous | 51.20 Years STANDARD_DEVIATION 9.06 | 54.80 Years STANDARD_DEVIATION 9.536 | 58.18 Years STANDARD_DEVIATION 9.444 | 52.92 Years STANDARD_DEVIATION 9.509 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 6 Participants | 28 Participants | 12 Participants | 10 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment China | 6 Participants | 28 Participants | 12 Participants | 10 Participants |
| Sex: Female, Male Female | 4 Participants | 14 Participants | 7 Participants | 3 Participants |
| Sex: Female, Male Male | 2 Participants | 14 Participants | 5 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 6 / 6 | 10 / 10 | 12 / 12 |
| serious Total, serious adverse events | 1 / 6 | 2 / 10 | 1 / 12 |
Outcome results
Primary
Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)
A summary of AEs and SAEs considered by the investigator to be drug-related is located in the Reported Adverse Events module. An AE is summarized if the onset date is on or after the first dose of study drug and within 30 days after the last dose, or it occurred before the first dose of study drug and worsened while on the therapy.
Time frame: Baseline through Study Completion (Up to 12 Weeks)
Population: All enrolled participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) | Drug-Related Adverse Event | 4 Participants |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) | Serious Adverse Event | 0 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) | Drug-Related Adverse Event | 8 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) | Serious Adverse Event | 1 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) | Drug-Related Adverse Event | 10 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) | Serious Adverse Event | 0 Participants |
Primary
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab
Cycle 1 analysis performed: Area Under the Concentration-Time Curve Zero to Infinity (AUC\[0-∞\]); Cycle 2 analysis performed: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC\[τ,ss\])
Time frame: Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)
Population: All enrolled participants who received at least one dose of study drug and had evaluable AUC(0-∞) for Cycle 1 and AUC(τ,ss) for Cycle 2 PK data.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 2 AUC(τ,ss) (n = 1, 6, 8) | NA Microgram*day/milliliter (µg*day/mL) | — |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 1 AUC(0-∞) (n = 5, 7, 7) | 870 Microgram*day/milliliter (µg*day/mL) | Geometric Coefficient of Variation 14 |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 1 AUC(0-∞) (n = 5, 7, 7) | 1430 Microgram*day/milliliter (µg*day/mL) | Geometric Coefficient of Variation 31 |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 2 AUC(τ,ss) (n = 1, 6, 8) | 1630 Microgram*day/milliliter (µg*day/mL) | Geometric Coefficient of Variation 32 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 1 AUC(0-∞) (n = 5, 7, 7) | 1350 Microgram*day/milliliter (µg*day/mL) | Geometric Coefficient of Variation 9 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 2 AUC(τ,ss) (n = 1, 6, 8) | 1540 Microgram*day/milliliter (µg*day/mL) | Geometric Coefficient of Variation 16 |
Primary
Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab
Time frame: Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)
Population: All enrolled participants who received at least one dose of study drug and had evaluable Cmax pharmacokinetics (PK) data.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab | Cycle 1 (n = 6, 9, 12) | 155 microgram/milliliter (µg/mL) | Geometric Coefficient of Variation 13 |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab | Cycle 2 (n = 1, 6, 8) | NA microgram/milliliter (µg/mL) | — |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab | Cycle 1 (n = 6, 9, 12) | 186 microgram/milliliter (µg/mL) | Geometric Coefficient of Variation 22 |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab | Cycle 2 (n = 1, 6, 8) | 219 microgram/milliliter (µg/mL) | Geometric Coefficient of Variation 22 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab | Cycle 1 (n = 6, 9, 12) | 190 microgram/milliliter (µg/mL) | Geometric Coefficient of Variation 39 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab | Cycle 2 (n = 1, 6, 8) | 239 microgram/milliliter (µg/mL) | Geometric Coefficient of Variation 19 |
Primary
Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab
Time frame: Cycle 2-5: Predose
Population: All enrolled participants who received at least one dose of study drug and had evaluable Cmin PK data.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 3 (n = 1, 2, 5) | NA µg/mL | — |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 2 (n = 5, 8, 10) | 36.9 µg/mL | Geometric Coefficient of Variation 35 |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 4 (n = 1, 2, 4) | NA µg/mL | — |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 5 (n = 0, 3, 4) | NA µg/mL | — |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 5 (n = 0, 3, 4) | 56.5 µg/mL | Geometric Coefficient of Variation 17 |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 3 (n = 1, 2, 5) | NA µg/mL | — |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 4 (n = 1, 2, 4) | NA µg/mL | — |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 2 (n = 5, 8, 10) | 29.5 µg/mL | Geometric Coefficient of Variation 90 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 5 (n = 0, 3, 4) | 92.5 µg/mL | Geometric Coefficient of Variation 19 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 2 (n = 5, 8, 10) | 59.7 µg/mL | Geometric Coefficient of Variation 26 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 4 (n = 1, 2, 4) | 79.6 µg/mL | Geometric Coefficient of Variation 26 |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab | Cycle 3 (n = 1, 2, 5) | 68.7 µg/mL | Geometric Coefficient of Variation 28 |
Secondary
Duration of Response
Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. For each participant who is not known to have died or to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, duration of tumor response was to be censored at the date of the participant's last objective tumor assessment prior to that cut-off date.
Time frame: Time Between Meeting Response Criteria and Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)
Population: All enrolled participants who received at least one dose of study drug. There were no participants censored due to no CR or PR responses.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Duration of Response | 0 Months |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Duration of Response | 0 Months |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Duration of Response | 0 Months |
Secondary
Duration of Stable Disease (SD)
Duration of SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. SD is measured at the start of the study drug until progressive disease or death due to any cause, whichever is first. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.
Time frame: Baseline to Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)
Population: All enrolled participants who received at least one dose of study drug and had evaluable SD data. Participants censored for Cohort 1, 2, and 3: 3, 2, and 1, respectively.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Duration of Stable Disease (SD) | NA Months |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Duration of Stable Disease (SD) | 5.68 Months |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Duration of Stable Disease (SD) | 5.29 Months |
Secondary
Number of Participants With Anti-Ramucirumab Antibodies
A sample will be considered positive for circulating anti-ramucirumab antibodies if it exhibits a post-baseline antibody level that exceeds the upper 95% confidence interval of the mean determined from the normal anti-ramucirumab level seen in healthy untreated individuals. A participant will be considered to have an anti-ramucirumab response if there are 2 consecutive positive samples or if the final sample tested is positive.
Time frame: Cycle 1: Pre-infusion, Cycle 2: Pre-infusion, Cycle 3: Pre-infusion
Population: All enrolled participants who received at least one dose of study drug and had evaluable immunogenicity data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With Anti-Ramucirumab Antibodies | 0 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With Anti-Ramucirumab Antibodies | 0 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With Anti-Ramucirumab Antibodies | 0 Participants |
Secondary
Number of Participants With Best Objective Response (BOR)
Participants achieved disease control if they had a BOR of CR, PR or SD. Progressive Disease (PD) and those participants which were Not Evaluable (NE) were also reported. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.
Time frame: Baseline to Progressive Disease or Participant Stopped Study (Up to 10 Weeks)
Population: All enrolled participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Progressive Disease (PD) | 3 Participants |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Stable Disease (SD) | 3 Participants |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Complete Response (CR) | 0 Participants |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Partial Response (PR) | 0 Participants |
| Cohort 1: 6 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Not Evaluable (NE) | 0 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Stable Disease (SD) | 7 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Complete Response (CR) | 0 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Partial Response (PR) | 0 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Progressive Disease (PD) | 3 Participants |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Not Evaluable (NE) | 0 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Not Evaluable (NE) | 1 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Progressive Disease (PD) | 3 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Complete Response (CR) | 0 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Stable Disease (SD) | 8 Participants |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Number of Participants With Best Objective Response (BOR) | Partial Response (PR) | 0 Participants |
Secondary
Time to Disease Progression
Time to progressive disease was measured from the start of study drug until progressive disease. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.
Time frame: Baseline to Progressive Disease (Up to 10 Weeks)
Population: All enrolled participants who received at least one dose of study drug. Censoring for Cohort 1, 2 and 3: 3, 2 and 2, respectively.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: 6 mg/kg/2w Ramucirumab | Time to Disease Progression | 1.41 Months |
| Cohort 2: 10 mg/kg/3w Ramucirumab | Time to Disease Progression | 3.38 Months |
| Cohort 3: 8 mg/kg/2w Ramucirumab | Time to Disease Progression | 3.94 Months |